Hypercalcemia of Malignancy.

Mimi I Hu

Journal: Endocrinology and metabolism clinics of North America 2022;50(4):721-728

PMID: 34774243

Full Text on Elsevier Science View on PubMed

Abstract

Hypercalcemia of malignancy (HCM) is considered an oncologic emergency associated with significant symptom burden and increased comorbid conditions and mortality. Underlying pathologic processes most often stimulate osteoclast-mediated bone resorption. Although long-term control of HCM depends on effective management of the underlying cancer, temporizing management strategies for acute and/or symptomatic HCM include hydration and antiresorptive bone-modifying agents. Although most patients respond well to the antiresorptive therapies available, further investigation into other agents for those who are refractory to both bisphosphonates and denosumab is needed.

Address: Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1461, Houston, TX 77030, USA. Electronic address: [email protected].

DOI: 10.1016/j.ecl.2021.07.003

Link outs

Free resources

Medical:

https://medlineplus.gov/cancer.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Bone Density Conservation Agents, Denosumab, Diphosphonates, Humans, Hypercalcemia, Neoplasms, Paraneoplastic Syndromes